Literature DB >> 1368317

Antisense oligonucleotides as antiviral agents.

S Agrawal1.   

Abstract

Antisense oligonucleotides are an attractive potential alternative to conventional drugs as antiviral agents. A major advantage is the relatively simple rational design of oligonucleotides which should bind only to specific nucleic acid sequences, compared with conventional drugs which are frequently targeted against sites of unknown structure in proteins. Progress to date provides hope for the development of a new class of antiviral chemotherapeutics based on antisense oligonucleotides.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1368317     DOI： 10.1016/0167-7799(92)90203-8

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN： 0167-7799            Impact factor:   19.536


  24 in total

1.  Inhibitory effects of EGFR antisense oligodeox ynucleotide in human colorectal cancer cell line.

Authors:  Yong He; Jun Zhou; Jin-Sheng Wu; Ke-Feng Dou
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

2.  Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes.

Authors:  P L Nicklin; D Bayley; J Giddings; S J Craig; L L Cummins; J G Hastewell; J A Phillips
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

3.  Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide.

Authors:  V Prasad; S Hashim; A Mukhopadhyay; S K Basu; R P Roy
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  Synthesis of specific diastereomers of a DNA methylphosphonate heptamer, d(CpCpApApApCpA), and stability of base pairing with the normal DNA octamer d(TPGPTPTPTPGPGPC).

Authors:  E V Vyazovkina; E V Savchenko; S G Lokhov; J W Engels; E Wickstrom; A V Lebedev
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

5.  Sequence identity of the n-1 product of a synthetic oligonucleotide.

Authors:  J Temsamani; M Kubert; S Agrawal
Journal:  Nucleic Acids Res       Date:  1995-06-11       Impact factor: 16.971

6.  Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates.

Authors:  J Lisziewicz; D Sun; V Metelev; P Zamecnik; R C Gallo; S Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

7.  A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection.

Authors:  M A Biasolo; A Radaelli; L Del Pup; E Franchin; C De Giuli-Morghen; G Palu
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.

Authors:  G S Robinson; E A Pierce; S L Rook; E Foley; R Webb; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

Review 9.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

10.  Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity.

Authors:  J Y Tang; J Temsamani; S Agrawal
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.